Affinity Asset Advisors, LLC
- SEC CIK
- 0001773195
- Latest filing
- Aug 13, 2026
XENE holding history
Xenon Pharmaceuticals Inc. in every 13F filed by Affinity Asset Advisors, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
XENE overviewAll 13F holders of XENEFull Q2 2026 holdings
- Shares (Q2 2026)
- 1,595,000
- Value
- $96.3M
- % of portfolio
- 4.7%
- Quarters held
- 18
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,595,000 | $96.3M | 4.7% | −80,000−4.8% | Reduced | Holders |
| Q1 2026 | 1,675,000 | $97.4M | 5.7% | +425,000+34.0% | Added | Holders |
| Q4 2025 | 1,250,000 | $56.0M | 4.0% | −150,000−10.7% | Reduced | Holders |
| Q3 2025 | 1,400,000 | $56.2M | 5.2% | +300,000+27.3% | Added | Holders |
| Q2 2025 | 1,100,000 | $34.4M | 5.1% | −228,175−17.2% | Reduced | Holders |
| Q1 2025 | 1,328,175 | $44.6M | 7.0% | +166,938+14.4% | Added | Holders |
| Q4 2024 | 1,161,237 | $45.5M | 7.1% | +17,216+1.5% | Added | Holders |
| Q3 2024 | 1,144,021 | $45.0M | 7.0% | +149,794+15.1% | Added | Holders |
| Q2 2024 | 994,227 | $38.8M | 6.1% | +156,840+18.7% | Added | Holders |
| Q1 2024 | 837,387 | $36.0M | 5.9% | +377,387+82.0% | Added | Holders |
| Q4 2023 | 460,000 | $21.2M | 4.2% | +159,562+53.1% | Added | Holders |
| Q3 2023 | 300,438 | $10.3M | 3.4% | +240,062+397.6% | Added | Holders |
| Q2 2023 | 60,376 | $2.32M | 0.9% | −29,624−32.9% | Reduced | Holders |
| Q1 2023 | 90,000 | $3.22M | 1.2% | +40,000+80.0% | Added | Holders |
| Q4 2022 | 50,000 | $1.97M | 0.9% | +50,000 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −80,000−100.0% | Sold out | Holders |
| Q1 2022 | 80,000 | $2.45M | 1.0% | −70,500−46.8% | Reduced | Holders |
| Q4 2021 | 150,500 | $4.70M | 2.0% | +100,500+201.0% | Added | Holders |
| Q3 2021 | 50,000 | $764.0K | 0.3% | +50,000 | New | Holders |